CoChat
Sign Up
Cited by 35

The DOI matches its Crossref record, with a small difference in title or year; 7 of the 7 references it cites were found in a registry or an index.

The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation

Susan-Resiga, Delia, Girard, Emmanuelle, Kiss, Robert Scott, Essalmani, Rachid, Hamelin, Josée, Asselin, Marie-Claude, Awan, Zuhier, Butkinaree, Chutikarn, Fleury, Alexandre, Soldera, Armand, Dory, Yves L., Baass, Alexis, Seidah, Nabil G.·2017·Journal of Biological Chemistry
DOI 10.1074/jbc.m116.769430
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m116.769430

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Endogenous ASGR1 has two bands likely representing a major mature form of approximately 48 kDa and a minor ER-localized immature form of approximately 42 kDa.

    “Note the presence of two bands for endogenous ASGR1 (Fig. 2B), likely representing a major mature form (∼48 kDa) that excited the endoplasmic reticulum (ER) and a minor ER-localized immature form (∼42 kDa), as observed in other proteins (16, 17).”

    From Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin (2021) · cites this paper as [16]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. Brown, 1986, A receptor-mediated pathway for cholesterol homeostasis, Science, 232, 34, 10.1126/science.3513311 · DOI · Paper page
  2. Fokkema, 2011, LOVD Version 2.0: the next generation in gene variant databases, Hum. Mutat, 32, 557, 10.1002/humu.21438 · DOI
  3. Jeon, 2005, Structure and physiologic function of the low density lipoprotein receptor, Annu. Rev. Biochem, 74, 535, 10.1146/annurev.biochem.74.082803.133354 · DOI · Paper page
  4. Hobbs, 1992, Molecular genetics of the LDL receptor gene in familial hypercholesterolemia, Hum. Mutat, 1, 445, 10.1002/humu.1380010602 · DOI · Paper page
  5. Sørensen, 2006, Retention of mutant low density lipoprotein receptor in endoplasmic reticulum (ER) leads to ER stress, J. Biol. Chem, 281, 468, 10.1074/jbc.M507071200 · DOI
  6. Ranheim, 2006, Model system for phenotypic characterization of sequence variations in the LDL receptor gene, Clin. Chem, 52, 1469, 10.1373/clinchem.2006.068627 · DOI
  7. Etxebarria, 2015, Functional characterization and classification of frequent low density lipoprotein receptor variants, Hum. Mutat, 36, 129, 10.1002/humu.22721 · DOI · Paper page
  8. Koivisto, 2001, A novel cellular phenotype for familial hypercholesterolemia due to a defect in polarized targeting of LDL receptor, Cell, 105, 575, 10.1016/S0092-8674(01)00371-3 · DOI · Paper page
  9. Bottomley, 2009, Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants, J. Biol. Chem, 284, 1313, 10.1074/jbc.M808363200 · DOI
  10. Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl. Acad. Sci. U.S.A, 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  11. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet, 34, 154, 10.1038/ng1161 · DOI · Paper page
  12. Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low density lipoprotein receptor knockout phenotype, Proc. Natl. Acad. Sci. U.S.A, 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
  13. Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J. Biol. Chem, 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  14. Nassoury, 2007, The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR, Traffic, 8, 718, 10.1111/j.1600-0854.2007.00562.x · DOI · Paper page
  15. Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat. Struct. Mol. Biol, 14, 413, 10.1038/nsmb1235 · DOI · Paper page
  16. Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. U.S.A, 105, 1820, 10.1073/pnas.0712064105 · DOI · Paper page
  17. Lo Surdo, 2011, Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH, EMBO Rep, 12, 1300, 10.1038/embor.2011.205 · DOI · Paper page
  18. McNutt, 2009, Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HEPG2 cells, J. Biol. Chem, 284, 10561, 10.1074/jbc.M808802200 · DOI
  19. Seidah, 2014, PCSK9: a key modulator of cardiovascular health, Circ. Res, 114, 1022, 10.1161/CIRCRESAHA.114.301621 · DOI
  20. Bertolini, 2013, Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy, Atherosclerosis, 227, 342, 10.1016/j.atherosclerosis.2013.01.007 · DOI
  21. Lind, 2004, Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment, J. Intern. Med, 256, 406, 10.1111/j.1365-2796.2004.01401.x · DOI
  22. Langslet, 2015, Evolocumab (AMG 145) for primary hypercholesterolemia, Expert Rev. Cardiovasc. Ther, 13, 477, 10.1586/14779072.2015.1030395 · DOI
  23. Huijgen, 2012, Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low density lipoprotein-receptor sequence variants, Eur. Heart J, 33, 2325, 10.1093/eurheartj/ehs038 · DOI
  24. Awan, 2012, Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial, Clin. Chem, 58, 183, 10.1373/clinchem.2011.172932 · DOI
  25. Pedersen, 2014, Low density lipoprotein receptor class A repeats are O-glycosylated in linker regions, J. Biol. Chem, 289, 17312, 10.1074/jbc.M113.545053 · DOI · Paper page
  26. Lee, 1998, Proteasome inhibitors: valuable new tools for cell biologists, Trends Cell Biol, 8, 397, 10.1016/S0962-8924(98)01346-4 · DOI · Paper page
  27. Poirier, 2009, Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation: evidence for an intracellular route, J. Biol. Chem, 284, 28856, 10.1074/jbc.M109.037085 · DOI · Paper page
  28. Denis, 2012, Gene inactivation of PCSK9 reduces atherosclerosis in mice, Circulation, 125, 894, 10.1161/CIRCULATIONAHA.111.057406 · DOI · Paper page
  29. Poirier, 2016, Trafficking dynamics of PCSK9-induced LDLR degradation: focus on human PCSK9 mutations and C-terminal domain, PLoS ONE, 11, e0157230, 10.1371/journal.pone.0157230 · DOI
  30. Abifadel, 2012, Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia, Atherosclerosis, 223, 394, 10.1016/j.atherosclerosis.2012.04.006 · DOI
  31. Weider, 2016, Proprotein convertase subtilisin/kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation, J. Biol. Chem, 291, 16659, 10.1074/jbc.M116.717736 · DOI
  32. Roubtsova, 2015, PCSK9 deficiency unmasks a sex/tissue-specific subcellular distribution of the LDL and VLDL receptors in mice, J. Lipid Res, 56, 2133, 10.1194/jlr.M061952 · DOI · Paper page
  33. Pitas, 1981, Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy, Arteriosclerosis, 1, 177, 10.1161/01.ATV.1.3.177 · DOI
  34. Beglova, 2004, Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor, Mol. Cell, 16, 281, 10.1016/j.molcel.2004.09.038 · DOI
  35. Brown, 1983, Recycling receptors: the round-trip itinerary of migrant membrane proteins, Cell, 32, 663, 10.1016/0092-8674(83)90052-1 · DOI · Paper page
  36. Aulinskas, 1985, Retro-endocytosis of low density lipoprotein by cultured human skin fibroblasts, Arteriosclerosis, 5, 45, 10.1161/01.ATV.5.1.45 · DOI
  37. Beglova, 2005, The LDL receptor: how acid pulls the trigger, Trends Biochem. Sci, 30, 309, 10.1016/j.tibs.2005.03.007 · DOI · Paper page
  38. Zaid, 2008, Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low density lipoprotein receptor degradation and critical role in mouse liver regeneration, Hepatology, 48, 646, 10.1002/hep.22354 · DOI · Paper page
  39. Awan, 2014, The effect of insulin on circulating PCSK9 in postmenopausal obese women, Clin. Biochem, 47, 1033, 10.1016/j.clinbiochem.2014.03.022 · DOI
  40. Rudenko, 2002, Structure of the LDL receptor extracellular domain at endosomal pH, Science, 298, 2353, 10.1126/science.1078124 · DOI · Paper page
  41. Brown, 1997, LDL-receptor structure. Calcium cages, acid baths and recycling receptors, Nature, 388, 629, 10.1038/41672 · DOI · Paper page
  42. Denis, 2011, Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells, J. Proteome Res, 10, 2011, 10.1021/pr2000072 · DOI
  43. Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low density lipoprotein receptor, Proc. Natl. Acad. Sci. U.S.A, 105, 13045, 10.1073/pnas.0806312105 · DOI · Paper page
  44. Benjannet, 2006, The proprotein convertase PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J. Biol. Chem, 281, 30561, 10.1074/jbc.M606495200 · DOI · Paper page
  45. Holla, 2011, Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors, J. Lipid Res, 52, 1787, 10.1194/jlr.M018093 · DOI · Paper page
  46. Saavedra, 2012, The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway, J. Biol. Chem, 287, 43492, 10.1074/jbc.M112.394023 · DOI
  47. Canuel, 2013, Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1), PLoS ONE, 8, e64145, 10.1371/journal.pone.0064145 · DOI · Paper page
  48. Raal, 2013, Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high dose statin therapy, J. Am. Heart Assoc, 2, e000028, 10.1161/JAHA.112.000028 · DOI
  49. Tavori, 2013, Serum proprotein convertase subtilisin/kexin type 9 and cell surface low density lipoprotein receptor: evidence for a reciprocal regulation, Circulation, 127, 2403, 10.1161/CIRCULATIONAHA.113.001592 · DOI · Paper page
  50. Topchiy, 2016, Lipopolysaccharide is cleared from the circulation by hepatocytes via the low density lipoprotein receptor, PLoS ONE, 11, e0155030, 10.1371/journal.pone.0155030 · DOI
  51. Rader, 2014, Lomitapide and mipomersen: two first-in-class drugs for reducing low density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, Circulation, 129, 1022, 10.1161/CIRCULATIONAHA.113.001292 · DOI
  52. Dubuc, 2010, A new method for measurement of total plasma PCSK9: clinical applications, J. Lipid Res, 51, 140, 10.1194/jlr.M900273-JLR200 · DOI
  53. Essalmani, 2011, In vivo evidence that furin from hepatocytes inactivates PCSK9, J. Biol. Chem, 286, 4257, 10.1074/jbc.M110.192104 · DOI · Paper page
  54. Vassiliou, 1994, Exogenous receptor-associated protein binds to two distinct sites on human fibroblasts but does not bind to the glycosaminoglycan residues of heparan sulfate proteoglycans, J. Biol. Chem, 269, 15172, 10.1016/S0021-9258(17)36588-2 · DOI
  55. Pronk, 2013, GROMACS 4.5: a high throughput and highly parallel open source molecular simulation toolkit, Bioinformatics, 29, 845, 10.1093/bioinformatics/btt055 · DOI
  56. Lindorff-Larsen, 2010, Improved side-chain torsion potentials for the Amber ff99SB protein force field, Proteins, 78, 1950, 10.1002/prot.22711 · DOI
  57. Jorgensen, 1983, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys, 79, 926, 10.1063/1.445869 · DOI
  58. Darden, 1993, Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems, J. Chem. Phys, 98, 10089, 10.1063/1.464397 · DOI
  59. Berendsen, 1984, Molecular dynamics with coupling to an external bath, J. Chem. Phys, 81, 3684, 10.1063/1.448118 · DOI
  60. Parrinello, 1981, Polymorphic transitions in single crystals: a new molecular dynamics method, J. Appl. Phys, 52, 7182, 10.1063/1.328693 · DOI
  61. Vendome, 2011, Molecular design principles underlying β-strand swapping in the adhesive dimerization of cadherins, Nat. Struct. Mol. Biol, 18, 693, 10.1038/nsmb.2051 · DOI
  62. Kuzmanic, 2010, Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors, Biophys. J, 98, 861, 10.1016/j.bpj.2009.11.011 · DOI
  63. Van Der Spoel, 2005, GROMACS: fast, flexible, and free, J. Comput. Chem, 26, 1701, 10.1002/jcc.20291 · DOI

Cited by

Sorted by citations

Metadata

Authors
Susan-Resiga, D., Girard, E., Kiss, R. S., Essalmani, R., Hamelin, J., Asselin, M.-C., Awan, Z., Butkinaree, C., Fleury, A., Soldera, A., Dory, Y. L., Baass, A., & Seidah, N. G.
ORCID
Seidah, Nabil G.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2017-02
Volume
292
Issue
5
Pages
1573-1590
ISSN
0021-9258
DOI
10.1074/jbc.m116.769430
Cited by
35
References
7
Language
en
Licence
Funders
  • Canadian Institutes of Health Research (148363)
  • Canada Excellence Research Chairs, Government of Canada (216684)
  • Pfizer (W1207162)
  • Fondation Leducq (13CVD03)
  • University of Pennsylvania (MDBR-15-211-FH)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review